Baillie Gifford
Search results
Jun 3, 2024 · Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
Apr 11, 2024 · If you’re passionate about engineering with biology, please join us! We're building a platform to make biology easier to engineer, and we're building it for you. Watch on.
Jul 12, 2024 · Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum.
Aug 24, 2021 · The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of ...
Apr 11, 2024 · Bioworks3 is home to Ginkgo's DNA synthesis BIOFAB and the Build platform, synthesizing and assembling designed genes and pathways.
4 days ago · Biotechnology specialist Ginkgo Bioworks (NYSE: DNA) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with ...
4 days ago · Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution . BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...
May 11, 2021 · Ginkgo Bioworks is going public via a merger with former MGM CEO Harry Sloan's SPAC in a deal that values the biotech company at $15 billion.
Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.
